Slide continues for pSivida, Alimera after FDA rejection

Iluvien

Shares of pSivida Corp. (NSDQ:PSDV) and Alimera Sciences (NSDQ:ALIM) slid today on an FDA rejection of their Iluvien drug-device combination.

The federal watchdog agency said it couldn’t approve Iluvien, a back-of-the-eye implant designed to treat diabetic macular edema, because Alimera hadn’t proven that its benefits outweigh its safety risks. The FDA wants Alimera, which licenses the device from pSivida, to conduct two more clinical studies for Iluvien for DME.

pSivida shares fell 12.0 percent today to $1.40, hitting a 52-week low of $1.36 along the way and adding to the nearly 50 percent lost Friday, after the FDA decision was announced.*

Sign up to get our free newsletters delivered straight to your inbox

“I can only reiterate how surprised and disappointed we were by this news. We have had two other back-of-the-eye products previously approved by the FDA and we were optimistic that the FDA would approve Iluvien for DME,” pSivida CEO Dr. Paul Ashton told analysts on a conference call. “Because we have licensed Iluvien to Alimera, the next steps for Iluvien development in DME in the US will be decided by Alimera, not us. We don’t participate in running the clinical trials or developing the regulatory strategy for the DME program.”

ALIM shares suffered as well, dropping 276 percent Friday and another 5.2 percent today, hitting it’s own 52-week low of $1.39 on the way to a $1.50 close.

Alimera has asked the FDA for a meeting to discuss next steps and is suspending a clinical trial the FDA asked for until at least until that meeting, Alimera CEO Daniel Myers told analysts during a separate call.

“Overall, we were surprised and disappointed with the FDA’s decision,” Myers said. “We are committed to and, with approximately $39 million in cash as of Sept. 30, have the funds for evaluating our options in the U.S. and pursuing approval in Europe.”

Alimera has applied for approval from the U.K., Austria, France, Germany, Italy, Portugal and Spain and expects to hear from EU regulatory authorities in the first half of 2012, Myers said.

pSivida’s Ashton said European approval doesn’t trigger a payment, as with the $25 million it would have been due with an FDA green light. But, like the U.S. deal, EU approval does come with 20 percent royalties on European sales and 33 percent of non-royalty payments from any third-party distribution deals.

The company had $21.3 million in net cash as of Sept. 30, he added, “sufficient to support our clinical and planned operations into at least calendar 2013. As those of you who follow us know, now we are a very frugal company.”

And then there’s a second indication for the Iluvien implant to consider: posterior uveitis. Ashton said the FDA decision on DME doesn’t preclude U.S. approval for the uveitis indication, because the two diseases are so different.

“We will be having a meeting with the FDA shortly to better understand what they will need to see for approval for this insert of posterior uveitis and how the FDA’s decision on DME would affect an application in uveitis,” he said during the call. “Now just to reiterate, we don’t believe that the recent decision on the Iluvien in DME will affect our ability to reference the data directed by Alimera in its DME development program. These data include clinical, non-clinical data, manufacturing and stability data and offers the substantial savings in cost and time and if we proceed to offer this for uveitis. However, we certainly plan to discuss the most efficient use of these data with the FDA if we decide to move forward in uveitis.”

pSivida is also co-developing, along with pFizer (NYSE:PFE), a biodegradable insert designed to treat glaucoma and high intraocular pressure, Ashton added.

“So this product is a different insert, as you are looking at different drugs for a different disease than Iluvien for DME,” he said.

*Correction, Nov. 16, 2011: This article originally mis-stated the percentage value lost by PSDV shares between Nov. 10 and Nov. 11. Return to the corrected sentence.

RSS From Medical Design & Outsourcing

  • Molex delivers ISO 13485-compliant, medical-grade surgical cables from its class 100,000 clean room facility
    Molex, LLC operates a fully ISO 146441-1:1999 Class 8-certified clean room, satisfying strict particulate contamination levels specified by ISO-compliant requirements. Located in Thailand, the facility has less than 100,000 particulates (≥0.5µm) per cubic foot of air and manufactures a variety of ISO 13485-compliant medical cables and surgical cables used in operating theatres, hospitals, laboratories and […]
  • Swept-Source OCT: Patent license agreement between Massachusetts General Hospital and Heidelberg Engineering
    Heidelberg Engineering has entered into a patent license agreement with Massachusetts General Hospital (MGH) in Boston. The agreement grants global and exclusive rights to 77 basic patents and patent applications which relate to swept-source OCT technology and its application in ophthalmology. Spectral domain OCT has become indispensable to eye care professionals worldwide to diagnose and […]
  • MIT’s MultiFab presents a stark challenge to incumbent 3D Printer manufacturers’ hardware, software, and business Models
    MIT’s Computational Fabrication Group recently announced the MultiFab, a low-cost 3D printer that can combine up to 10 different resins in one part and also includes a 3D scanning system to identify and fix errors during production. According to Lux Research, these capabilities are rare in commercial 3D printers today due to the manufacturers’ need […]
  • AVX releases Accu-P MP medical grade film chip capacitors for medical devices
    AVX Corporation, a leading manufacturer of passive components and interconnect solutions, has released a new series of thin film chip capacitors specifically designed to meet the demanding performance specifications for implantable medical devices. Delivering extremely tight capacitive tolerances, exceptionally repeatable performance, and remarkably low ESR and high Q at high frequencies—including VHF, UHF, and RF […]
  • RIVANNA commences manufacturing of its Accuro device
    Rivanna Medical announced that it has begun manufacturing its FDA-cleared Accuro device, a handheld and untethered smart-phone-sized device that is designed to guide spinal anesthesia with automated 3D navigation technology in addition to ultrasound imaging of abdominal, musculoskeletal, cardiac and peripheral vascular anatomies. The product will be launched at the ASA annual meeting in San […]
  • FDA seeks public input on Quality Metrics guidance
    by Oliver Wolf, Senior Product Manager, MasterControl In line with the general shift towards risk-driven approaches in the quality management world, FDA is now taking steps towards applying those same principles to its own auditing schedule. At the end of July, the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation […]
  • First ‘Ear Wear’ for Active Adults Debuts with MDHearingAid FIT
    If you’ve burned out your ears with earbuds, headphones or decades of other audio abuse but aren’t ready for your grandmother’s hearing aids, not to worry! The new MDHearingAid FIT gets you back in the game with a tiny, FDA-registered, one-size-fits-most solution that doesn’t block your ear canal like old-fashioned in-the-ear hearing aids. The FIT feels […]
  • CardioGenics enters into manufacturing agreement with Ontario-based Plasticap
    CardioGenics Holdings, developer for the In-Vitro-Diagnostics (“IVD”) testing market, announced that it has entered into a manufacturing agreement with Plasticap of Ontario, Canada, pursuant to which Plasticap will manufacture CardioGenics’ proprietary self-metering cartridges for its QL Care analyzer. The term of the agreement is three years and the purchase price for each cartridge shall be […]
  • MTD Micro Molding releases micro materials menu
    MTD Micro Molding, a long-time leader in micro-injection molding, has released an updated “Materials Menu” of materials that can be successfully micromolded to help guide engineers at medical device companies. Material selection is a crucial step in product manufacturability. The correct material drives tolerance, dimension, strength, usabality, speed-to-market, design, critical features, and cost. Through MTD’s […]
  • MedTech Chat: Elastic technology for drug delivery
    Dr. Zhen Gu and Dr. Yong Zhu from North Carolina State University are both co-senior authors of a research paper describing their recent work. Dr. Gu, Dr. Zhu and other researchers from North Carolina State University and the University of North Carolina at Chapel Hill have developed a drug delivery technology that consists of an […]
  • B. Braun’s OEM Division offers large bore normally closed low-pressure check valves
    Infusion therapy and pain management device manufacturer B. Braun said today it is offering normally closed large-bore low-pressure check valves through its valve-focused contract manufacturing OEM division. The valves, offered by Bethlehem, Pa.-based B. Braun, are designed for the intermittent injection of fluids during medical treatment and open automatically when pressure is applied. The newly […]

Leave a Reply